Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 6/20 | 0.42 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.36 |
| ▸ | MLNR | O43193 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21481808 | 0.92 | PTGER4 (0.42) | MCHR1CNR2ROCK2HRH3PRKAA2 | |
| SCHEMBL21458205 | 0.92 | PTGER4 (0.42) | MCHR1CNR2ROCK2HRH3PRKAA2 | |
| SCHEMBL30038185 | 0.92 | CNR2 (0.45) | MCHR1CNR2PRKAA2ITKCNR1 | |
| SCHEMBL21458194 | 0.91 | MCHR1 (0.39) | MCHR1CNR2ROCK2HRH3PRKAA2 | |
| SCHEMBL31203500 | 0.91 | MCHR1 (0.39) | MCHR1CNR2ROCK2HRH3PRKAA2 | |
| SCHEMBL21482125 | 0.91 | MCHR1 (0.39) | MCHR1CNR2ROCK2HRH3PRKAA2 | |
| SCHEMBL21481876 | 0.89 | CNR2 (0.41) | CNR2ROCK2CNR1 | |
| SCHEMBL21481810 | 0.85 | MCHR1 (0.43) | MCHR1CNR2HRH3PRKAA2ADORA1 | |
| SCHEMBL21482124 | 0.84 | MCHR1 (0.42) | MCHR1CNR2HRH3PRKAA2ADORA1 | |
| SCHEMBL21481950 | 0.83 | PI4KB (0.37) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | MCHR1 1023/4885CNR2 3/4885ROCK2 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.